



## Available online at www.sciencedirect.com



Regulatory Toxicology and Pharmacology 42 (2005) 209-217

Regulatory Toxicology and **Pharmacology** 

www.elsevier.com/locate/yrtph

# Health effects classification and its role in the derivation of minimal risk levels: Reproductive and endocrine effects

Hana R. Pohl a,\*, Bryan Luukinen b, James S. Holler a

a Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services, Atlanta, GA, USA b Internship Fellow Oak Ridge Institute for Science and Education, US Department of Energy, Oak Ridge, TN, USA

> Received 7 February 2005 Available online 24 May 2005

#### Abstract

)

The Agency for Toxic Substances and Disease Registry (ATSDR) derives health-based guidance values called minimal risk levels (MRLs) to assist with assessment of risks posed by exposures to hazardous chemicals. From the total of 326 MRLs currently posted on ATSDR's web site (www.atsdr.cdc.gov), 14 and 5 MRLs are based on reproductive and endocrine endpoints, respectively. The paper also describes the ranking of effects into less serious and serious categories according to ATSDR's Guidance for Developing Toxicological Profiles, endpoints used for the MRLs derivation, and the use of uncertainty factors. Published by Elsevier Inc.

Keywords: Reproductive effects; Health guidance values; MRL; RfC; RfD

### 1. Introduction

In recent years, numerous studies have suggested that many environmentally persistent chemicals have a potential to disrupt normal functions of the endocrine system. Many chemicals have also serious impact on reproductive and developmental endpoints in humans and animals. Assessment of risks posed by chemicals causing reproductive effects and protection of future generations are important public health tasks.

To determine the levels of significant human exposure to a given chemical and associated health effects, Agency for Toxic Substances and Disease Registry's (ATSDR's) toxicological profiles examine and interpret available toxicological and epidemiological data. As described in the preceding papers (Chou et al., 1998; Pohl and Abadin, 1995), ATSDR categorizes the health effects according to their seriousness as "serious," "less serious," or "minimal." A "less-serious" effect is defined as changes

0273-2300/\$ - see front matter. Published by Elsevier Inc. doi:10.1016/j.yrtph.2005.04.004

that will prevent an organ or organ system from functioning in a normal manner but will not necessarily lead to the inability of the whole organism to function normally (Pohl and Abadin, 1995). "Serious" effects are effects that prevent the organism from functioning normally or can cause death. "Minimal" effects are those that reduce the capacity of an organ or organ system to absorb additional toxic stress but will not necessarily lead to the inability of the organ or organ system to function normally.

ATSDR uses the highest no-observed-adverse-effect level (NOAEL) or the lowest-observed-adverse-effect level (LOAEL) in the available literature to derive a health-based guidance value called a minimal risk level (MRL). An MRL is defined as "an estimate of the daily human exposure to a substance that is likely to be without an appreciable risk of adverse, noncancer effects over a specified duration of exposure" (ATSDR, 1992a,b). MRLs are derived for inhalation and oral exposures. For each route of exposure, MRLs can be derived for acute (up to 14 days), intermediate (15–364 days), and chronic (365 days or more) durations.

Corresponding author. Fax: +1 770 488 4178. E-mail address: hpohl@cdc.gov (H.R. Pohl).

Human data are preferred; however, human equivalent levels can be derived based on animal exposure. The formula for derivation of an oral MRL is

$$MRL = \frac{NOAEL(LOAEL)}{(UF \times MF)},$$

where MRL is the minimal risk level (mg/kg/day), NOAEL is the no-observed-adverse-effect level (mg/kg/day), LOAEL is the lowest-observed-adverse-effect level (mg/kg/day), UF is the uncertainty factor (unitless), and MF is the modifying factor (unitless).

UFs are used to account for uncertainties associated with extrapolation from a LOAEL to a NOAEL and from animal to human data, and with adjustments for intraspecies variability. MFs may be applied to reflect additional scientific judgement on the database. The above concept is also used for the reference dose (RfD) derivation by U.S. Environmental Protection Agency (EPA) (Barnes and Dourson, 1988). MRLs provide health professionals with a concept of exposure levels at which adverse health effects are not expected in human populations living in the vicinity of hazardous waste sites or chemical emissions.

The purpose of this review was to inform the public about MRLs based on reproductive and endocrine effects and about the guidance provided for the sections of toxicological profiles describing these health effects and their categorization in the ATSDR's Guidance for Developing Toxicological Profiles (ATSDR, 2003a,b). So far, the guidance has served as an internal document and has not been released to the public. However, parts of the guidance related to neurological, developmental, and respiratory effects and respective MRLs based on these effects were previously published (Chou and Williams-Johnson, 1998; Pohl et al., 1998; Wilbur, 1998).

## 2. Materials and methods

The MRLs were based on vast databases compiled in the toxicological profiles for acrylonitrile (ATSDR, 1990), atrazine (ATSDR, 2003a,b), cyanide (ATSDR, 1997), RDX [1,3,5,-triaza-1,3,5-trinitrocyclohexane] (ATSDR, 1995a,b,c), di(2-ethylhexyl)phthalate (ATSDR, 2002a,b,c,d), diethyl phthalate (ATSDR, 1995a,b,c), hexachlorobenzene (ATSDR, 2002a,b,c,d), methoxychlor (ATSDR, 2002a,b,c,d), dibromochloropropane (ATSDR, 1992a,b), 1,3-dinitrobenzene and 1,3,5-trinitrobenzene (ATSDR, 1995a,b,c), chlorophenols (ATSDR, 1999), 2,4- and 2,6-dinitrotoluene (ATSDR, 1998a,b), iodine (ATSDR, 2001a,b), pentachlorophenol (ATSDR, 2001a,b), and polybrominated biphenyls (PBBs) and polybrominated diphenyl ethers (PBDEs) (ATSDR, 2002a,b,c,d). Toxicological profiles (final and draft documents) can be found on ATSDR's website (www.atsdr.cdc.gov). The MRLs were derived according to the current ATSDR methodology (Chou et al., 1998; Pohl and Abadin, 1995). A list of all current MRLs (updated on May 11, 2004) is available on ATSDR's website (www.atsdr.cdc.gov).

#### 3. Results

## 3.1. Reproductive effects and related MRLs

Reproductive toxicity is defined as a dysfunction induced by a chemical, physical, and or other agent that affects the process of gametogenesis from its earliest stage to implantation of the conceptus in the endometrium. Reproductive studies were conducted for numerous chemicals. The studies differ not only in their quality, but also in the sensitivity of parameters measured. These include pathological and histopathological changes in organ and cellular structures together with pathophysiological changes in male and female reproductive systems, and reproductive outcomes for both sexes. Examples of reproductive effect end points are listed and classified as less serious or serious according to the ATSDR guidance document (ATSDR, 2003a,b) in Table 1. It is recognized that for some effects, there is a continuum in the severity and the whole clinical

Table 1
Reproductive effect end points

Effect	Less serious	Serious
Abnormal sperm <sup>a</sup> (morphology,		+
count, motility)		
Abortion		+
Atrophy		+
Decreased fertility <sup>b</sup>	+	+
Decreased litters		+
Decreased spermatogenesis <sup>a</sup>	+	+
Degeneration of epididymides <sup>b</sup>	+	+
Disrupted spermatogenesis		+
Females: no reproduction		+
Maternal toxicity		+
Increased estrus		+
Irreversible histological change in testes		+
Ovarian dysfunction		+
Ovary weight change	+	
Postimplantation loss		+
50% reduction in number of offspring		+
Sterility		+
Testicular atrophy		+
Testicular degeneration	+	+
Granuloma epididymides <sup>c</sup>	+	+
Tubular degeneration		+
Tubule edema	+	
Vaginal bleeding	+	

<sup>&</sup>lt;sup>a</sup> Variability exists among normal/less serious/serious; e.g., a normal human semen specimen has a volume of 3-4 mL, a sperm count of  $30 \times 10^6$ , and 80% morphologically normal and motile spermatozoa.

		•	

<sup>&</sup>lt;sup>b</sup> The effect can be less serious or serious depending upon the degree.
<sup>c</sup> This condition can be considered serious because it can lead to progressive fibrosis.

H.R. Pohl et al. / Regulatory Toxicology and Pharmacology 42 (2005) 209-217

picture has to be evaluated. for the correct classification. For example, organ weight changes for ovaries or testes are considered less-serious effects. A definitive organ dysfunction along with the atrophy (weight change) of ovaries or testes is a serious effect.

Although the ovaries and testes have endocrine functions, for reasons of consistency among the toxicological profiles ATSDR's guidance recommends categorization of effects involving these functions as reproductive effects.

As of May 2004, ATSDR listed 14 MRLs based on reproductive effects. These MRLs and the specific endpoints that served as the bases for their derivation are listed in Table 2. As an example, some MRLs that are no longer valid, because they were supplanted by new MRLs based on updated information, are also listed in the table. They are further discussed in the text.

Because of its noninvasive nature, collection of sperm is one of the easiest way to evaluate the male reproductive system in humans. Sperm number, structure, maturation, motility, viability, and function (i.e., cervical-mucus penetrations and sperm-oocyte interactions) also are the tests most often performed in laboratory animals. They are, therefore, also the basis for MRL derivation for a number of chemicals (e.g., acrylonitrile, cyanide, di(2-ethyl-hexyl)phthalate, 1,2-dibromo-3-chloropropane, and 1,3-dinitrobenzene).

In some instances, the sperm tests were supplemented with data from evaluation of histopathological changes in testes and epididymis (e.g., acrylonitrile and 1,3-dinitrobenzene). Evaluation of testicular degeneration varied across the studies from crude measurements of testicular and epididymal weights (cyanide), to light-microscopic examination revealing tubular degeneration (1,3-dinitrobenzene), and more advanced electron-microscopic examination describing Leydig cell mitochondrial swelling, focal dilatation, and vesiculation of the smooth endoplasmic reticulum (diethyl phthalate). In addition, hormonal changes served as end points for deriving MRLs for the methoxychlor and 1,2-dibromo-3-chloropropane. In fact, for some chemicals that are known toxicants to the male reproductive system, such as 1,2-dibromo-3-chloropropane, changes in hormonal levels provide early warnings of the chemically induced toxicity (ATSDR, 1992a,b). MRLs for atrazine, hexachlorobenzene, and methoxychlor were based on effects in the female reproductive system. The chemicals caused hormonal changes, histopathological changes (degeneration of primordial follicles), and early onset of puberty (early estrus), respectively.

Effects on the developing embryo are important in the evaluation of reproductive in utero effects. Fertilization, implantation of blastocyst, and gastrulation can be evaluated. Chemical insult in this stage is expressed mostly as embryonic death and resorption. Developmental effects are distinguished from reproductive effects by evaluation of the conceptus after implantation. MRLs

for di(2-ethylhexyl) phthalate, white phosphorus, and 2,4,6-trichlorophenol were based on the measurement of actual reproductive outcome.

211

For the derivation of MRLs, standard default uncertainty factors (UF) of 10 were used to extrapolate from a LOAEL to a NOAEL, from animals to humans, and for human susceptibility (for more information about the methodology, see Pohl and Abadin, 1995). There were several exceptions to this procedure. ATSDR used an UF of 3 to extrapolate from a LOAEL to a NOAEL in deriving an acute oral exposure MRL for diethyl phthalate. The LOAEL was deemed "minimal" because the testicular changes in rats were observable only under the electron microscope. Similarly, ATSDR used an UF of 3 for a "minimal" LOAEL for ultrastructural changes in ovaries confirmed by electron microscopy in monkeys exposed to hexachlorobenzene by oral route for intermediate duration. In case of the MRL for atrazine, a UF of 3 instead of 10 was used for human variability because the critical effect was identified in a sensitive population (young, developing female pigs). In contrast, ATSDR added a modifying factor (MF) of 3 for an MRL derived for RDX because of the lack of relevant neurological studies in the database. This step actually increased the uncertainty associated with the derived MRL.

## 4. Endocrine effects and related MRLs

As of May 2004, ATSDR's MRL Workgroup derived five MRLs based on endocrine effects (excluding reproductive hormones changes). MRLs based on changes of reproductive hormones (FSH and prolactin in case of 1,2,-dibromo-3-chloropropane and methoxychlor, respectively) are described under reproductive effects above. Pathological and pathophysiological changes of thyroid gland and related upper regulatory hormones (i.e., TSH [thyroid stimulating hormone] from anterior pituitary gland) are often the subject of investigation of injury caused by endocrine disruptors. Table 3 lists MRLs that were based on thyroid effects. Relevant studies on endocrine effects other than those pertaining to thyroid and reproductive hormones are less frequent. No MRLs were based on these studies. The only notable deviation from applying the default uncertainty factors are the MRLs for iodine. UF of 1 was used for human susceptibility because of the robust database and available studies in children who are considered to be a sensitive population.

## 5. Discussion and conclusion

In recent years, attention has focused on the potential for a wide range of xenobiotic chemicals to interact with

Substance         Route         Duration         MRJ. value         UP         End point         Recreased speam count, tubular degeneration         Recreased point or all (1988)           Aczylonitrile         Onal         Intermediate         0.01 mg/kg/day         100 LOAEL in misc decreased speam count, tubular degeneration         Transformer all (1988)           RDX         Onal         Intermediate         0.05 mg/kg/day         100 NOAEL in misc decreased epiddymis, testis weight, spermatid heads,         NTP (1993)           RDX         Onal         Intermediate         0.03 mg/kg/day         100 NOAEL in misc decreased epiddymis, testis weight, spermatid heads,         NTP (1993)           Dig2-cthylhnex/llphthalare         Onal         Acute         1.06 NOAEL in misc decreased epiddymis, testis weight, delayed spermatid         Acute         Acute           Dig2-cthylhex/llphthalare         Onal         Acute         1.06 NOAEL in misc decreased epiddymis, testis weight, delayed spermatid         Acute	MINES DASED OIL IEPIODUCIIVE CIICCIS	וברוז					
Oral Intermediate   0.01 mg/kg/day   1000   LOAEL in mice; decreased sperm count, tubular degeneration   Oral Intermediate   0.05 mg/kg/day   100   LOAEL in rats; decreased cyclidymis, testis weight, spermatid heads, spermatid counts at higher dose   O.05 mg/kg/day   100   NOAEL in rats; testicular degeneration at higher dose   Oral Intermediate   0.03 mg/kg/day   100   NOAEL in rats; testicular degeneration at higher dose   Oral Intermediate   0.10 mg/kg/day   100   NOAEL in rats; testicular degeneration at higher dose   Oral Intermediate   0.10 mg/kg/day   100   NOAEL in rats; testicular degeneration at higher dose   Oral   Acute   0.06 mg/kg/day   100   NOAEL in rats; testicular degeneration at higher dose   Oral   Intermediate   0.001 mg/kg/day   100   NOAEL in rats; aspermatiogenesis at higher dose   Oral   Intermediate   0.001 mg/kg/day   100   LOAEL in rats; begin microhondrial swelfing, focal dilatation, and vasiculation of the smooth endoplasmic reticulum   Acute   0.001 mg/kg/day   100   LOAEL in rats; perceitaed mating   Oral   Intermediate   0.002 mg/kg/day   100   LOAEL in rats; precorous vaginal opening, more severe effects at higher dose   Oral   Intermediate   0.002 mg/kg/day   100   LOAEL in rats; precorous vaginal opening, more severe   Oral   Acute   0.002 mg/kg/day   100   LOAEL in rats; precorous vaginal opening, more severe   Oral   Intermediate   0.002 mg/kg/day   100   LOAEL in rats; precorous vaginal opening, more severe   Oral   Intermediate   0.003 mg/kg/day   100   LOAEL in rats; prematoroa, histological changes   Oral   Intermediate   0.004 mg/kg/day   100   LOAEL in rats; changes in gestational index   Intermediate   0.004 mg/kg/day   100   LOAEL in rats; changes in gestational index   Intermediate   0.004 mg/kg/day   100   LOAEL in rats; creased oral interprecaped changes in gestational index   Intermediate   0.004 mg/kg/day   100   LOAEL in rats; creased principles or at higher dose   Intermediate   0.004 mg/kg/day   100   LOAEL in rats; increased cumper of stillorn paps	Substance	Route	Duration	MRL value	UF	End point	Reference
Oral   Intermediate   0.003 mg/kg/day   100   NOAEL in rats; decreased epitidymis, testis weight, spermatid heads, permatid one of mg/kg/day   100   NOAEL in rats; testicular degeneration at higher dose	Acrylonitrile	Oral	Intermediate	0.01 mg/kg/day	1000	LOAEL in mice; decreased sperm count, tubular degeneration	Tandon et al. (1988)
Oral Intermediate   0.05 mg/kg/day   100   NOAEL in ratis, decreased epididymis, testis weight, spermatid heads, spermatid counts at higher dose state   1 mg/kg/day   300   NOAEL in ratis; reduced testicular weight, delayed spermatid maturation at higher dose   1 mg/kg/day   100   NOAEL in ratis; reduced testicular weight, delayed spermatid maturation at higher dose   1 mg/kg/day   100   NOAEL in ratis; reduced testicular weight, delayed spermatid maturation at higher dose   1 mg/kg/day   100   NOAEL in ratis; reduced testicular weight, delayed spermatid maturation at higher dose   1 mg/kg/day   100   NOAEL in ratis; aspermatogenesis at higher doses   1 mg/kg/day   100   LOAEL in ratis; apermatogenesis and higher doses   1 ntermediate   0.001 mg/kg/day   1000   LOAEL in mink; decreased mumber of oocytes; ultrastructural   1 ntermediate   0.005 mg/kg/day   1000   LOAEL in mink; decreased mumber of oocytes; ultrastructural   1 ntermediate   0.005 mg/kg/day   1000   LOAEL in ratis; precocious vaginal opening, more severe effects at higher doses   1 ntermediate   0.002 mg/kg/day   1000   LOAEL in ratis; precocious vaginal opening, more severe effects at higher dose   1 ntermediate   0.002 mg/kg/day   1000   LOAEL in ratis; precocious vaginal opening, more severe effects at higher dose   1 ntermediate   0.002 mg/kg/day   1000   LOAEL in ratis; decreased esticular epithelium, decreased spermatozoa, histological changes in permatozoa, histological changes in morphology, decreased spermatozoa, morphology decreased spermatozoa, histological changes in nephalogical changes in gestational index   1 ntermediate   0.002 mg/kg/day   1000   LOAEL in ratis; changes in gestational index   1 ntermediate   0.002 mg/kg/day   1000   LOAEL in ratis; changes in gestational index   1 ntermediate   0.002 mg/kg/day   1000   LOAEL in ratis; changes in gestational index   1 ntermediate   0.002 mg/kg/day   1000   LOAEL in ratis; increased enumber of stillborn pups	Atrazine	Oral	Intermediate	0.003 mg/kg/day	300	LOAEL in pigs; serum 17 β-estradiol, changes in estrus cycle	Gojmerac et al. (1999)
Oral   Intermediate   0.03 mg/kg/day   300   NOAEL in rats; resticular degeneration at higher dose   1 mg/kg/day   100   NOAEL in rats; resticular weight, delayed spermatid   mg/kg/day   100   NOAEL in rats; resticular weight, delayed spermatid   mauration at higher dose   mauration at higher dose   mauration at higher dose   Oral   Chronic   0.06 mg/kg/day   100   NOAEL in rats; aspermatogenesis at higher doses   Oral   Intermediate   0.0001 mg/kg/day   100   LOAEL in monkeys; decreased namber of occytes; ultrastructural degeneration of ovarian primordial follicles   Oral   Intermediate   0.001 mg/kg/day   100   LOAEL in rats; accelerated onse of occytes; ultrastructural degeneration of ovarian primordial follicles   Oral   Intermediate   0.001 mg/kg/day   100   LOAEL in rats; accelerated onse of puberty in females   Oral   Intermediate   0.002 mg/kg/day   100   LOAEL in rats; accelerated onse of puberty in females   Oral   Intermediate   0.002 mg/kg/day   100   LOAEL in rats; precoclous vaginal opening, more severe effects at higher dose   Oral   Intermediate   0.002 mg/kg/day   100   LOAEL in rats; decreased morphology, decreased   Spermatogenesis   Intermediate   0.008 mg/kg/day   100   LOAEL in rats; damaged testicular epithelium, decreased spermatozoa, morphological changes in spermatozoa, histological changes   Oral   Intermediate   0.008 mg/kg/day   100   LOAEL in rats; changes in gestational index   Oral   Intermediate   0.004 mg/kg/day   100   LOAEL in rats; increased number of stillborn pups	Cyanide	Oral	Intermediate	0.05 mg/kg/day	100	NOAEL in rats; decreased epididymis, testis weight, spermatid heads, spermatid counts at higher dose	NTP (1993)
te Oral Acute 1 mg/kg/day 100 NOAEL in rats; reduced testicular weight, delayed spermatid maturation at higher dose 10.1 mg/kg/day 100 NOAEL in rats; aspermatogenesis at higher doses 10.0001 mg/kg/day 100 NOAEL in rats; aspermatogenesis at higher doses 10.0001 mg/kg/day 100 NOAEL in rats; aspermatogenesis at higher doses 10.0001 mg/kg/day 100 LOAEL in rats; aspermatogenesis at higher doses 10.0001 mg/kg/day 100 LOAEL in rats; aspermatogenesis at higher doses 10.0001 mg/kg/day 100 LOAEL in rats; accelerated onset of puberty in females of 2.000 mg/kg/day 100 LOAEL in mink; decased mating degeneration of ovarian primordial folicles 10.001 mg/kg/day 1000 LOAEL in rats; precoious vaginal opening, more severe effects at higher doses 10.002 mg/kg/day 1000 LOAEL in rats; precoious vaginal opening, more severe effects at higher dose 10.002 mg/kg/day 1000 LOAEL in rabbits; sperm abnormalities, increased serum FSH, reversible decreased spermatogenesis at higher dose 10.008 mg/kg/day 1000 LOAEL in rabbits; abnormal sperm morphology, decreased spermatogenesis in pigher dose 10.008 mg/kg/day 1000 LOAEL in rabbits; abnormal sperm morphology, decreased spermatozoa, histological changes in spermatozoa, histological changes in cpididymis at higher dose 10.008 mg/kg/day 1000 LOAEL in rats; damaged testicular epithelium, decreased spermatozoa, histological changes in cpididymis at higher dose 10.008 mg/kg/day 1000 LOAEL in rats; changes in gestational index 10.008 mg/kg/day 100 NOAEL in rats; changes in gestational index 10.0002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups	RDX	Oral	Intermediate	0.03 mg/kg/day	300	NOAEL in rats; testicular degeneration at higher dose	Army (1983)
te Oral Intermediate 0.1 mg/kg/day 100 NOAEL in rats; aspermatogenesis at higher doses Oral Chronic 0.06 mg/kg/day 100 NOAEL in rats; aspermatogenesis at higher doses Oral Intermediate 0.0001 mg/kg/day 1000 LOAEL in rats; Leydig cell mitochondrial swelling. Icoal dilatation, and vesiculation of the smooth endoplasmic reticulum degeneration of ovarian primordial follicles Oral Intermediate 0.0001 mg/kg/day 1000 LOAEL in rats; precederated onset of puberty in females Oral Intermediate 0.0002 ppm 100 LOAEL in rats; precederated onset of puberty in females opane Oral Intermediate 0.0002 mg/kg/day 1000 LOAEL in rats; precedicus vaginal opening, more severe effects at higher dose opane Oral Intermediate 0.002 mg/kg/day 1000 LOAEL in rabbits; sperm abnormalities, increased serum FSH, reversible decreased opana Acute 0.002 mg/kg/day 1000 LOAEL in rats; damaged testicular epithelium, decreased spermatozoa, morphological changes in gestational index  Oral Intermediate 0.008 mg/kg/day 1000 LOAEL in rats; changes in gestational index  Oral Intermediate 0.008 mg/kg/day 1000 LOAEL in rats; changes in gestational index  Oral Intermediate 0.002 mg/kg/day 1000 LOAEL in rats; changes in gestational proposes  Oral Intermediate 0.004 mg/kg/day 1000 NOAEL in rats; increased number of stillborn pups	Di(2-ethylhexyl)phthalate <sup>a</sup>	Oral	Acute	1 mg/kg/day	100	NOAEL in rats; reduced testicular weight, delayed spermatid maturation at higher dose	Dostal et al. (1988)
te Oral Chronic 0.06 mg/kg/day 100 NOAEL in rats; aspermatogenesis at higher doses  Oral Intermediate 0.0001 mg/kg/day 100 LOAEL in mats; Leydig cell mitochondrial swelling, focal dilatation, and vesiculation of the smooth endoplasmic reticulum and vesiculation of the smooth endoplasmic reticulum and vesiculation of ovarian primordial folicles  Oral Intermediate 0.001 mg/kg/day 1000 LOAEL in mink; deceased mating Oral Intermediate 0.002 ppm 100 LOAEL in rats; accelerated onset of puberty in females Oral Intermediate 0.002 ppm 100 NOAEL in rats; precocious vaginal opening, more severe effects at higher doses Oral Intermediate 0.002 mg/kg/day 100 NOAEL in rats; damaged testicular epithelium, decreased spermatogenesis Oral Intermediatechronic 1 pg/kg/day 100 NOAEL in rats; changes in spermatogoral changes Oral Intermediate 0.008 mg/kg/day 100 NOAEL in rats; changes in gestational index Oral Intermediate 0.004 mg/kg/day 100 NOAEL in rats; changes in gestational index Oral Intermediate 0.004 mg/kg/day 100 NOAEL in rats; changes in gestational index Oral Intermediate 0.008 mg/kg/day 100 NOAEL in rats; reduced mean litter size at higher dose Oral Intermediate 0.008 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups	Di(2-ethylhexyl)phthalate	Oral	Intermediate	0.1 mg/kg/day	100	NOAEL in mice; decreased fertility at higher doses	Lamb et al. (1987)
Oral         Acute         7 mg/kg/day         300         LOAEL in rats; Leydig cell mitochondrial swelling, focal dilatation, and vesiculation of the smooth endoplasmic reticulum of variant principles           Oral         Intermediate         0.0001 mg/kg/day         1000         LOAEL in monkeys; decreased number of oocytes; ultrastructural degeneration of ovarian principles           Oral         Acute         0.001 mg/kg/day         1000         LOAEL in rats; accelerated onset of puberty in females           Oral         Intermediate         0.005 mg/kg/day         1000         LOAEL in rats; accelerated onset of puberty in females           Oral         Intermediate         0.005 mg/kg/day         1000         LOAEL in rats; accelerated onset of puberty in females           Opane         Intermediate         0.005 mg/kg/day         1000         LOAEL in rats; precocious vaginal opening, more severe effects at higher doses           Opane         Oral         Intermediate         0.002 mg/kg/day         1000         LOAEL in rats; precocious vaginal opening, more severe effects at higher dose           Opane         Oral         Acute         0.002 mg/kg/day         1000         LOAEL in rats; damaged testicular epithelium, decreased spermatogenesis           Oral         Intermediatechronic         1 pg/kg/day         1000         LOAEL in rats; changes in gestational index           Oral         Intermedi	Di(2-ethylhexyl)phthalate	Oral	Chronic	0.06 mg/kg/day	100	NOAEL in rats; aspermatogenesis at higher doses	David et al. (2000)
Oral Intermediate 0.0001 mg/kg/day 90 LOAEL in monkeys; decreased number of oocytes; ultrastructural degeneration of ovarian primordial follicles Oral Acute 0.002 mg/kg/day 1000 LOAEL in ratis; accelerated onset of puberty in females Oral Intermediate 0.0002 ppm 100 LOAEL in ratis; accelerated onset of puberty in females effects at higher doses oral Intermediate 0.002 mg/kg/day 1000 LOAEL in rabbits; sperm abnormalities, increased serum FSH, reversible decreased spermatogenesis at higher dose oral Intermediatechronic 1 pg/kg/day 1000 LOAEL in ratis; damaged testicular epithelium, decreased spermatozoa, morphological changes in gestational index  Oral Intermediate 0.008 mg/kg/day 1000 LOAEL in ratis; changes in gestational index  Oral Intermediatechronic 1 pg/kg/day 1000 NOAEL in ratis; reduced mean litter size at higher dose Oral Intermediate 0.009 mg/kg/day 100 NOAEL in ratis; increased number of stillborn pups	Diethyl phthalate	Oral	Acute	7 mg/kg/day	300	LOAEL in rats; Leydig cell mitochondrial swelling, focal dilatation, and vesiculation of the smooth endoplasmic reticulum	Jones et al. (1993)
Oral Intermediate 0.001 mg/kg/day 1000 LOAEL in mink; deceased mating Oral Acute 0.02 mg/kg/day 1000 LOAEL in rats; accelerated onset of puberty in females Oral Intermediate 0.005 mg/kg/day 1000 LOAEL in rats; precocious vaginal opening, more severe effects at higher doses Oral Intermediate 0.002 mg/kg/day 1000 LOAEL in rabbits; sperm abnormalities, increased serum FSH, reversible decreased spermatogenesis at higher dose Oral Intermediatechronic 1 pg/kg/day 1000 NOAEL in rats; changes in gestational index Oral Intermediate 0.004 mg/kg/day 1000 NOAEL in rats; changes in gestational index Oral Intermediate 0.002 mg/kg/day 1000 NOAEL in rats; changes in gestational index Oral Intermediate 0.002 mg/kg/day 1000 NOAEL in rats; changes in gestational index Oral Intermediate 0.004 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups	Hexachloro-benzene	Oral	Intermediate	0.0001 mg/kg/day	90	LOAEL in monkeys; decreased number of oocytes; ultrastructural	Bourque et al. (1995),
Oral Intermediate 0.001 mg/kg/day 1000 LOAEL in mink; deceased mating Oral Acute 0.002 mg/kg/day 1000 LOAEL in rats; accelerated onset of puberty in females Oral Intermediate 0.0002 mg/kg/day 1000 LOAEL in rats; precocious vaginal opening, more severe effects at higher doses Oral Intermediate 0.0002 mg/kg/day 1000 LOAEL in rats; precocious vaginal opening, more severe effects at higher doses Oral Intermediatechronic 1 pg/kg/day 100 NOAEL in rats; changes in gestational index  Oral Intermediate 0.0002 mg/kg/day 100 NOAEL in rats; changes in gestational index  Oral Intermediate 0.0002 mg/kg/day 100 NOAEL in rats; changes in gestational index  Oral Intermediate 0.0002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups						degeneration of ovarian primordial follicles	Jarell et al. (1993)
Oral         Acute         0.02 mg/kg/day         1000         LOAEL in rats; precocious vaginal opening, more severe effects at higher doses           Opane         Inhal         Intermediate         0.005 mg/kg/day         1000         LOAEL in rats; precocious vaginal opening, more severe effects at higher doses           Opane         Inhal         Intermediate         0.0002 ppm         100         NOAEL in ratbits; sperm abnormalities, increased serum FSH, reversible decreased           opane         Oral         Acute         0.002 mg/kg/day         1000         LOAEL in ratbits; abnormal sperm morphology, decreased spermatogenesis at higher dose           Oral         Acute         0.008 mg/kg/day         100         NOAEL in rats; damaged testicular epithelium, decreased spermatozoa, histological changes in epididymis at higher dose           Oral         Intermediatechronic         1 pg/kg/day         100         LOAEL in rats; changes in gestational index           Oral         Intermediate         0.04 mg/kg/day         100         NOAEL in rats; reduced mean litter size at higher dose           Oral         Intermediate         0.002 mg/kg/day         100         NOAEL in rats; increased number of stillborn pups	Pentachlorophenol	Oral	Intermediate	0.001 mg/kg/day	1000	LOAEL in mink; deceased mating	Beard et al. (1997)
Oral Intermediate 0.005 mg/kg/day 1000 LOAEL in rats; precocious vaginal opening, more severe effects at higher doses  Oral Intermediate 0.002 ppm 100 NOAEL in rabbits; sperm abnormalities, increased serum FSH, reversible decreased spermatogenesis at higher dose spermatogenesis at higher dose 10.002 mg/kg/day 1000 LOAEL in rats; damaged testicular epithelium, decreased spermatozoa, northological changes in epididymis at higher dose 10.04 mg/kg/day 1000 NOAEL in rats; changes in gestational index  Oral Intermediate 0.04 mg/kg/day 1000 NOAEL in rats; reduced mean litter size at higher dose 10.0002 mg/kg/day 1000 NOAEL in rats; increased number of stillborn pups	Methoxychlor <sup>a</sup>	Oral	Acute	0.02 mg/kg/day	1000	LOAEL in rats; accelerated onset of puberty in females	Gray et al. (1989)
opane Inhal Intermediate 0.0002 ppm 100 NOAEL in rabbits; sperm abnormalities, increased serum FSH, reversible decreased spermatogenesis at higher dose spermatogenesis at higher dose spermatogenesis at higher dose spermatogenesis at higher dose spermatogenesis and higher dose spermatogenesis and promphological changes in epididymis at higher dose in termediate chronic I pg/kg/day 1000 NOAEL in rats; changes in gestational index  Oral Intermediate 0.04 mg/kg/day 100 NOAEL in rats; reduced mean litter size at higher dose Oral Intermediate 0.0002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups	Methoxychlor	Oral	Intermediate	0.005 mg/kg/day	1000	LOAEL in rats; precocious vaginal opening, more severe	Chapin et al. (1997)
ropane         Inhal         Intermediate         0.0002 ppm         100         NOAEL in rabbits; sperm abnormalities, increased serum FSH, reversible decreased           ropane         Oral         Intermediate         0.002 mg/kg/day         1000         LOAEL in rabbits; abnormal sperm morphology, decreased spermatogenesis at higher dose           Oral         Acute         0.008 mg/kg/day         100         NOAEL in rats; damaged testicular epithelium, decreased spermatozoa, histological changes in epididymis at higher dose           Oral         Intermediatechronic         1 pg/kg/day         100         LOAEL in rats; changes in gestational index           Oral         Intermediate         0.04 mg/kg/day         100         NOAEL in rats; reduced mean litter size at higher dose           Oral         Intermediate         0.002 mg/kg/day         100         NOAEL in rats; increased number of stillborn pups						effects at higher doses	
opane Oral Intermediate 0.002 mg/kg/day 1000 LOAEL in rabbits; abnormal sperm morphology, decreased spermatogenesis at higher dose spermatogenesis at higher dose normal sperm morphology, decreased spermatozoa, morphological changes in spermatozoa, histological changes in epididymis at higher dose normal intermediate 0.004 mg/kg/day 100 NOAEL in rats; reduced mean litter size at higher dose oral Intermediate 0.0002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups	1,2-Dibromo-3-chloropropane	Inhal	Intermediate	0.0002 ppm	100	NOAEL in rabbits; sperm abnormalities, increased serum FSH,	Rao et al. (1982)
opane Oral Intermediate 0.002 mg/kg/day 1000 LOAEL in rabbits; abnormal sperm morphology, decreased spermatogenesis Oral Acute 0.008 mg/kg/day 100 NOAEL in rats; damaged testicular epithelium, decreased spermatozoa, morphological changes in spermatozoa, histological changes in epididymis at higher dose Oral Intermediate 0.04 mg/kg/day 100 NOAEL in rats; reduced mean litter size at higher dose Oral Intermediate 0.002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups						spermatogenesis at higher dose	
Oral Acute 0.008 mg/kg/day 100 NOAEL in rats; damaged testicular epithelium, decreased spermatozoa, morphological changes in spermatozoa, histological changes  Oral Intermediate 0.04 mg/kg/day 100 NOAEL in rats; reduced mean litter size at higher dose  Oral Intermediate 0.002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups	1,2-Dibromo-3-chloropropane	Oral	Intermediate	0.002 mg/kg/day	1000	LOAEL in rabbits; abnormal sperm morphology, decreased	Foote et al. (1986a,b)
Oral Acute 0.008 mg/kg/day 100 NOAEL in rats, damaged testicular epithenum, decreased spermatozoa, morphological changes in spermatozoa, histological changes in epididymis at higher dose Oral Intermediate 0.04 mg/kg/day 100 NOAEL in rats; reduced mean litter size at higher dose Oral Intermediate 0.0002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups	-			2	•	spermatogenesis	
Oral Intermediatechronic 1 pg/kg/day 1000 LOAEL in rats; changes in gestational index  Oral Intermediate 0.04 mg/kg/day 100 NOAEL in rats; reduced mean litter size at higher dose  Oral Intermediate 0.0002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups	l,3-Dinitro-benzene	Oral	Acute	0.008 mg/kg/day	90	NOAEL in rats; damaged testicular epithelium, decreased spermatozoa, morphological changes in spermatozoa, histological changes	Linder et al. (1990)
Oral Intermediatechronic 1 pg/kg/day 1000 LOAEL in rats; changes in gestational index  Oral Intermediate 0.004 mg/kg/day 100 NOAEL in rats; reduced mean litter size at higher dose  Oral Intermediate 0.0002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups						in epididyinis at inglief dose	
Oral Intermediate 0.04 mg/kg/day 100 NOAEL in rats; reduced mean litter size at higher dose Oral Intermediate 0.0002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups	2,3,7,8-Tetrachloro- dibenzo- <i>p</i> -dioxin <sup>a</sup>	Oral	Intermediatechronic	l pg/kg/day	1000	LOAEL in rats; changes in gestational index	Murray et al. (1979)
Oral Intermediate 0.0002 mg/kg/day 100 NOAEL in rats; increased number of stillborn pups	2,4,6-Trichloro-phenola	Oral	Intermediate	0.04 mg/kg/day	100	NOAEL in rats; reduced mean litter size at higher dose	Exon and Koller (1985)
	White phosphorus	Oral	Intermediate	0.0002 mg/kg/day	100	NOAEL in rats; increased number of stillborn pups	IRDC (1985)

AEL = lowest-observed-adverse-effect level; MRL = minimal risk level; NOAEL = no-observed-ation exposure = 15 days to 365 days; chronic exposure = more than 1 year.

MRLs that were supplanted by new MRLs based on updated information or withdrawn.

- Linder, R.E., Strader, L.F., Barbee, R.R., et al., 1990. Reproductive toxicity of a single dose of 1,3-dinitrobenzene in two ages of young adult male rats. Fundam. Appl. Toxicol. 14, 284-298.
- Lopata, A., Martin, M., Oliva, K., Johnson, I., 1982. Embryonic development and embryo transfer. Fertil. Steril. 38, 682-687.
- Meistrich, M.L., 1982. Quantitative correlation between testicular stem cell survival, sperm production, and fertility in the mouse after treatment with different cytotoxic agents. J. Androl. 3, 58-71.
- Miller, J.F., Williamson, E., Glue, J., Gordon, Y.B., Grudzinskas, J.G., Sykes, A., 1980. Fetal loss after implantation. A prospective study. Lancet I, 554-556.

1

- Murray, F.J., Smith, F.A., Nitschke, K.D., Humiston, C.G., Kociba, R.J., Schwetz, B.A., 1979. Three-generation reproduction study of rats given 2,3,7,8-tetrachlorodibenzo-p-dioxin isomers using a polymeric liquid crystal capillary column. J. Chromatogr, 369 (1). 203-207.
- NTP (National Toxicology Program), 1993. National Toxicology Program Technical Report on toxicity studies of sodium evanide (CAS no. 143-33-9) administered in drinking water to F344/N rats and B6C3F1 mice. NIH Publication 94-3386. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD.
- NRC (National Research Council), 1994. Science and judgment in risk assessment. National Academy Press, Washington, DC.
- Paul, T., Meyers, B., Witorsch, R.J., et al., 1988. The effect of small increases in dietary iodine on thyroid function in euthyroid subjects. Metabolism 37 (2), 121-124.
- Perraud, J., 1976. Levels of spontaneous malformations in the CD rat and CD-1 mouse. Lab. Anim. Sci. 26, 293-300.
- Pohl, H., Abadin, H., 1995. Utilizing uncertainty factors in minimal risk levels derivation, Regul, Toxicol, Pharmacol, 22 (2), 180-188.
- Pohl, H., Smith-Simon, C., Hicks, H., 1998. Health effects classification and its role in the derivation of minimal risk levels: developmental effects. Regul. Toxicol. Pharmacol. 28, 55-60.
- Pohl, H.R., Hicks, H.E., Jones, D.E., Hansen, H., De Rosa, C.T., 2002. Public health perspectives on dioxin risks: two decades of evaluations. Hum. Ecol. Risk Assess. 8 (2), 233-250.

- Potashnik, G., Ben-Aderet, N., Israeli, R., et al., 1978. Suppressive effect of 1.2-dibromo-3-chloropropane on human spermatogenesis. Fertil. Steril. 30, 444-447.
- Rao, K.S., Burek, J.D., Murray, F.J., et al., 1982. Toxicologic and reproductive effects of inhaled 1,2-dibromo-3-chloropropane in male rabbits. Fundam, Appl. Toxicol. 2, 241–251.
- Rier, S.E., Martin, D.C., Bowman, R.E., et al., 1993. Endometriosis in Rhesus monkeys (Macaca mulatta) following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fundam, Appl. Toxicol. 21. 433-441
- Robaire, B., Smith, S., Hales, B.F., 1984. Suppression of spermatogenesis by testosterone in adult male rats: effect on fertility, pregnancy outcome and progeny. Biol. Reprod. 31, 221-
- Sandifer, S., Wilkins, R., Loadhold, C., et al., 1979. Spermatogenesis in agricultural workers exposed to dibromochloropropane (DBCP). Bull. Environ. Toxicol. 23, 703-710.
- Schantz, S.L., Ferguson, S.A., Bowman, R.E., 1992. Effects of 2,3,7,8tetrachlorodibenzo-p-dioxin on behavior of monkey in peer groups. Neurotoxicol. Teratol. 14, 433-446.
- Tandon, R., Saxena, D.K., Chandra, S.V., et al., 1988. Testicular effects of acrylonitrile in mice. Toxicol. Lett. 42, 55-63.
- Wheeler, J.M., 1992. Epidemiology and prevalences of endometriosis. Infertil, Reprod. Med. Clin. NA. 3, 545-549.
- WHO (World Health Organization), 1984. Environmental Health Criteria 30: Principles for Evaluating Health Risks to Progeny Associated with Exposure to Chemicals during Pregnancy. World Health Organization, Geneva.
- Whorton, M.D., Milby, T.H., Krauss, R.M., et al., 1979. Testicular function in DBCP exposed pesticide workers. J. Occup. Med. 21,
- Wilbur, S.B., 1998. Health effects classification and its role in the derivation of minimal risk levels: respiratory effects. J. Clean Technol. Environ. Toxicol. Occup. Med. 7 (3), 233-249.
- Zhou, T., Taylor, M.M., DeVito, M.J., et al., 2002. Developmental exposure to brominated diphenyl ethers results in thyroid hormone disruption, Toxicol. Sci. 66, 105-116.

213

- ATSDR (Agency for Toxic Substances and Disease Registry), 2003a. Guidance for the preparation of the seventeenth set toxicological profile. Agency for Toxic Substances and Disease Registry. U.S. Public Health Service. [Internal document].
- ATSDR (Agency for Toxic Substances and Disease Registry), 2003b.
  68 FR 63098. Revised priority list of hazardous substances that will be the subject of toxicological profiles. U.S. Public Health Service, Department of Health and Human Services, Atlanta, GA
- Barnes, D.G., Dourson, M., 1988. Reference dose (RfD): description and use in health risk assessments. Regul. Toxicol. Pharmacol. 8, 471-486
- Beard, A.P., Rawlings, N.C., 1998. Reproductive effects in mink (*Mustela vison*) exposed to the pesticides lindane, carbofuran and pentachlorophenol in a multigeneration study. J. Reprod. Fertil. 113 95-104
- Beard, A.P., McRae, A.C., Rawlings, A.C., 1997. Reproductive efficiency in mink treated with pesticides, lindane, carbofuran, and pentachlorophenol. J. Reprod. Fertil. 111, 21-28.
- Bourque, A.C., Singh, A., Lakhanpal, N., et al., 1995. Ultrastructural changes in ovarian follicule of monkeys administered hexachlorobenzene. Am. J. Vet. Res. 56, 1673–1677.
- Boyages, S.C., Bloot, A.M., Maberly, G.F., et al., 1989. Thyroid autoimmunity in endemic goitre caused by excessive iodine intake. Clin. Endocrinol. 31, 452–465.
- Boyd, J.A., Clark, G.C., Walmer, D.K., et al., 1995. Endometriosis and the environment biomarkers of toxin exposure. Abstract of Endometriosis 2000 Workshop, May 15–17.
- Chapin, R.E., Harris, M.W., Davis, B.J., et al., 1997. The effects of perinatal/juvenile exposure to methoxychlor on adult rat nervous, immune, and reproductive function. Fundam. Appl. Toxicol. 40, 138-157.
- Chou, C.H.S., Williams-Johnson, M., 1998. Health effects classification and its role in the derivation of minimal risk levels: neurological effects. Toxicol, Indust, Health 14 (3), 455-471.
- Chou, C.H.S., Holler, J., De Rosa, C.T., 1998. Minimal risk levels (MRLs) for hazardous substances. J. Clean Technol. Environ. Toxicol. Occup. Med. 7 (1), 1–24.
- Cummings, A.M., Metcalf, J.L., Birnbaum, L., 1996. Promotion of endometriosis by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats and mice: time-dose dependence and species comparison. Toxicol. Appl. Pharmacol. 138, 131-139.
- David, R.M., Moore, M.R., Finney, D.C., et al., 2000. Chronic toxicity of di(2-ethylhexyl) phthalate in rats. Toxicol. Sci. 55, 433– 443.
- De Rosa, C., Richter, P., Pohl, H., Jones, D., 1998. Environmental exposures that affect the endocrine system: public health implications. J. Toxicol. Environ. Health, part B: Crit. Rev. 1 (1), 3-26.
- De Rosa, C.T., Pohl, H.R., Hansen, H., Leonard, R., Holler, J., Jones, D.E., 1999. Reducing uncertainty in the derivation and application of health guidance values in public health practice: dioxin as a case study, In: Bailer, A.J., Maltoni, C. (Eds.), Uncertainty in the Risk Assessment of Environmental and Occupational Hazards. Ann. NY Acad. Sci. 895, 348–364.
- De Rosa, C.T., Pohl, H.R., Bencko, V., Richter, P., Jones, D.E., 2001a. Zdavotní rizika xenobiotik ovlivňujících endokrinnísystém. II. Důsledky pro zdraví člověka a strategie prevence. [Czech] Praktický Lékař 81 (11), 619-623.
- De Rosa, C.T., Pohl, H.R., Bencko, V., Richter, P., Jones, D.E.,
  2001b. Zdavotní rizika xenobiotik ovlivňujících endokrinní systém.
  I. Ekologické aspekty a mechanismus působení. [Czech] Praktický
  Lékař 81 (9), 490–494.
- Dostal, L.A., Chapin, R.E., Stefanski, SA., et al., 1988. Testicular toxicity and reduced Sertoli cell numbers in neonatal rats by di(2-ethyl-hexyl)phthalate and the recovery of fertility as adults. Toxicol. Appl. Pharmacol. 95, 104-121.

- Edmonds, D.K., Lindsay, K.S., Miller, J.F., Williamson, E., Wood, P.J., 1982. Early embryonic mortality in women. Fertil. Steril. 38, 447-453.
- EPA (U.S. Environmental Protection Agency), 1991. Guidelines for Developmental Toxicity Risk Assessment. Federal Register 56 (234), 63798-63826.
- EPA (U.S. Environmental Protection Agency), 1996. Guidelines for Reproductive Toxicity Risk Assessment. EPA/630/R-96/009. http://www.epa.gov/NCEA/raf/pdfs/repro51.pdf.
- EPA (U.S. Environmental Protection Agency), 1998. EPA Health Effects Test Guidelines OPPTS 870.3800, Reproduction and Fertility Effects, 12 pp.
- Exon, J.H., Koller, L.D., 1985. Toxicity of 2-chlorophenol, 2,4-dichlorophenol, and 2,4,6-trichlorophenol. In: Jolley, R.L. (Ed.), Water Chlorination: Chemistry, Environmental Impact and Health Effects. 5th Conference on Water Chlorination: Environmental Impact and Health Effects. Williamsburg, VA, June 1984, vol. 5, pp. 307–330.
- Foote, R.H., Berndtson, W.E., Rounsaville, T.R., 1986a. Use of quantitative testicular histology to assess the effects of dibromochloropropane (DBCP) on reproduction in rabbits. Fundam. Appl. Toxicol. 6, 638-647.
- Foote, R.H., Schermerhorn, E.C., Simkin, M.E., 1986b. Measurement of semen quality, fertility and reproductive hormones to assess dibromochloropropane (DBCP) effects in live rabbits. Fundam. Appl. Toxicol. 6, 628-637.
- Foster, W.G., Ruka, M.P., Gareau, P., et al., 1997. Morphologic characteristics of endometriosis in the mouse model: application to toxicology. Can. J. Physiol. Pharmacol. 75, 1188-1196.
- Fritz, H., Grauwiller, J., Hummler, H., Lindt, S., Schon, H., 1978. Collection of control data from teratologic experiments on mice, rats, and rabbits. Arzneim-Forsch 28, 1410–1413.
- Frohberg, H., 1977. An introduction to research in teratology. In: Neubert, D., Merker, H.J., Kwasigroch, T. (Eds.), Methods in Prenatal Toxicology. Georg Thieme Publ., Stuttgart, pp. 1-13.
- Glass, R.I., Lyness, R.N., Mengle, D.C., et al., 1979. Sperm count depression in pesticide applicators exposed to dibromochloropropane. Am. J. Epidemiol. 109, 346–351.
- Gojmerac, T., Uremovic, M., Uremovic, S., 1999. Reproduction disturbance caused by an s-triazine herbicide in pigs. Acta Vet. Hungarica 47 (1), 129–135.
- Gray, L.E., Ostby, J.S., Ferrell, J.M., et al., 1989. A dose-response analysis of methoxychlor-induced alterations of reproductive development and function in the rat. Fundam. Appl. Toxicol. 12, 92-108.
- IRDC, 1985. One generation reproductive study in rats with elemental phosphorus. International Research and Development Corporation. EPA/OTS Public Files, Washington, DC. IR 82-215. Fiche #OTS0518525-1. (Unpublished study).
- Jarell, J.F., Mc Mahon, A., Villeneuve, D., et al., 1993. Hexachlorobenzene in the monkey primordial germ cell without induced porphyria. Reprod. Toxicol. 7, 41-47.
- Johnson, K.L., Cummings, A.M., Birnbaum, L.S., 1997. Promotion of endometriosis in mice by polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls. Environ. Health. Perspect. 105, 750– 755.
- Jones, H.B., Garside, D.A., Liu, R., et al., 1993. The influence of phthalate esters on Leydig cells structure and function in vitro and in vivo. Exp. Mol. Pathol. 58, 179-193.
- Kimmel, C.A., Kavlock, R.J., Francis, E.Z., 1992. Animal models for assessing developmental toxicity. In: Guzelian, P.S., Henry, C.J., Olin, S.S. (Eds.), Similarities and Differences between Children and Adults: Implications for Risk Assessment. International Life Sciences Institute (ILSI) Press, Washington, DC.
- Lamb, J.C., Chapin, R.E., Teague, I., et al., 1987. Reproductive effects in four phthalic acid esters in the mouse. Toxicol. Appl. Pharmacol. 88, 255–269.

Table 3
MRLs based on endocrine effects

Substance	Route	Duration	MRL value (mg/kg/day)	UF	End point	Reference
Iodine	Oral	Acute	0.01	1	LOAEL in humans; subclinical hypothyroidism	Paul et al. (1988)
Iodine	Oral	Chronic	0.005	1	LOAEL in humans; subclinical hypothyroidism with gland enlargement	Boyages et al. (1989)
Pentachlorophenol	Oral	Chronic	0.001	1000	LOAEL in mink; decreased serum thyroxine and decreased relative thyroid weight	Beard and Rawlings (1998)
Polybrominated biphenyls	Oral	Acute	0.01	100	NOAEL in rats; decreased serum levels of thyroid T <sub>4</sub> hormone	Allen-Rowlands et al. (1981)
Polybrominated diphenyl ethers	Oral	Acute	0.03	30	LOAEL in rats; reduced serum T <sub>4</sub> in fetuses	Zhou et al. (2002)

LOAEL = lowest-observed-adverse-effect level; MRL = minimal risk level; NOAEL = no-observed-adverse-effect level; UF= uncertainty factor. Acute exposure = up to 14 days; intermediate-duration exposure = 15 days to 365 days; chronic exposure = more than 1 year.

and disrupt the endocrine systems of humans and animals (De Rosa et al., 1998, 2001a,b). ATSDR's Priority List of Hazardous Substances lists about 300 substances found at hazardous waste sites. The substances are ranked by priority based on the frequency of occurrence at waste sites, toxicity, and potential for human exposure (ATSDR, 2003a,b). Well over half of those substances are metals and organochlorine compounds, two major classes of chemicals associated with disruption of the endocrine system. Many of these chemicals cause a wide range of health effects including endocrine, reproductive, and developmental effects (De Rosa et al., 1998, 2001a,b).

Health guidance values reflect the application of a range of default assumptions that are conservative (i.e., protective) and which are believed, in aggregate, to result in protective health guidance values. As explained previously, to account for recognized areas of uncertainty regarding species variability in effect(s) and effect levels, sensitive human populations, and low-dose extrapolation, UF are used in developing health guidance values. The application of such UF contributes to the protective nature of health guidance values. The limitations, assumptions, and uncertainties inherent in health risk assessment are addressed in the National Academy of Sciences report "Science and Judgment in Risk Assessment" (NRC, 1994). In this report, the Academy states that "uncertainty analysis should be an iterative process, moving from the identification of generic uncertainties" to more refined analyses of uncertainties. Further uncertainties include differences in bioavailability of chemicals, background exposures, background prevalence of diseases (health effects), possible misclassification of effects, etc. Some examples of uncertainties and limitations are discussed here.

To understand the mechanisms by which chemicals cause reproductive effects, it is necessary to have a basic understanding of the physiologic interrelationships of the various components of the endocrine and reproductive systems, the multiple control mechanisms, and the pathology (gross and histological) of the targeted

organs. It is easy to make an erroneous conclusion regarding the cause of a reproductive effect based on limited observations at a single time point. Therefore, a battery of tests often is recommended (WHO, 1984).

All MRLs presented in this paper, except those for iodine, were based on effects observed in animals. Even for chemicals well known to target human reproductive system, such as 1,2-dibromo-3-chloropropane, a health-based guidance value related to observed effects in humans is difficult to derive. Most available data came from occupational settings, in case of 1,2-dibromo-3-chloropropane, from cohorts of workers exposed to this nematocide during production at factories (Potashnik et al., 1978; Whorton et al., 1979), and from cohorts of applicators and farmers (Glass et al., 1979; Sandifer et al., 1979) and actual levels of exposure were not established. Animal studies intended to investigate reproductive effects should follow certain protocols that were outlined elsewhere (EPA, 1991, 1996, 1998; FDA, 1993). Hence, animal studies in laboratory settings provide more reliable information for risk assessment. However, a detailed description of protocols relevant to the assessment of reproductive and endocrine outcomes is beyond the scope of this paper (ATSDR, 2003a,b).

Basing the health guidance values on animal studies brings another set of problems. Despite controlled laboratory conditions and rigid protocols, the animal data have several confounding factors. Some of the concerns are related to actual delivered dose, end point classification, windows of susceptibility, and relevance of animal data to humans. For example, the preimplantation and early postimplantation background losses in rats are low, less than 10% (Fritz et al., 1978; Frohberg, 1977; Perraud, 1976), whereas the spontaneous fetal abortions in humans may be as high as 50% (Edmonds et al., 1982; Lopata et al., 1982; Miller et al., 1980). Evaluation of interspecies differences always should play an important role in the derivation of MRLs. From our data set, an intermediate-duration oral MRL for 2,4,6-trichlorophenol was based on a NOAEL for reduced litter size (p < 0.10) observed in rats at higher doses. Another study with chlorophenols indicated an increased trend in percentage of preimplantation loss in rats. Although no data on reproductive effects of chlorophenols in humans are available, this end point is considered relevant for consideration in human risk assessment. The statistical increase in losses linked to the exposure similarly could be reflected in humans by a further increase in losses above the already high background levels.

Although many chemicals are considered endocrine disruptors and/or reproductive toxicants, other end points in their database were more sensitive and appropriate for MRL derivations. A chronic oral MRL for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can illustrate deliberations to select a proper end point (ATSDR, 1998a,b). TCDD exposure in rats and mice enhanced surgically induced endometriosis. Significant increases in the diameter of the endometriotic site and an acceleration of growth were observed in rats (Cummings et al., 1996) and mice (Cummings et al., 1996; Johnson et al., 1997), respectively. However, Foster et al. (1997) noted that preexposure to TCDD resulted in endometriosis development due to immune suppression rather than an estrogen-responsive disease. Rier et al. (1993) found a dose-related increase in the incidence and severity of endometriosis in monkeys chronically exposed to TCDD in a diet. However, monkeys appear to be more susceptible to endometriosis, based on a 30% background incidence of endometriosis in monkeys (Rier et al., 1993) compared with a 10% background incidence in humans (Wheeler, 1992). Thus, if the derivation of a chronic oral MRL were based on endometriosis would necessitate using an uncertainty factor of less than 1 (or, at most, 1) to account for the higher sensitivity of monkeys to endometriosis as compared to humans. This would result in a computed MRL essentially the same as the chronic oral MRL of 1 pg/kg/day based on developmental toxicity (Schantz et al., 1992) as described in the toxicological profile (ATSDR, 1998a,b). Moreover, (1) the clinical history for these rhesus monkeys during the period between the Schantz et al. (1992) study and the Rier et al. (1993) examination conducted 10 years later is unknown (not reported); (2) Boyd et al. (1995) did not find an association between exposure to chlorinated dibenzo-p-dioxins (CDDs), chlorinated dibenzofurans (CDFs), or polychlorinated biphenyls (PCBs) and endometriosis in a clinical study in women; (3) the U.S. Environmental Protection Agency (EPA) (1997) concluded that "the evidence for supporting the hypothesis that CDDs and PCBs are causally related to human endometriosis via an endocrine-disruption mechanism is very weak." Therefore, even though information indicates that endometriosis also may be a sensitive toxicological end point for TCDD exposure, the neurobehavioral developmental end point (altered social behavior) reported in the Schantz et al. (1992) study was determined

to be the most appropriate end point for deriving an MRL for chronic oral exposure to TCDD.

Table 2 also lists some of the MRLs that have been supplanted by new MRLs based on more recent evaluations of the updated database (i.e., new data being published on the profiled chemicals). For example, ATSDR has withdrawn the previous MRL of 0.02 mg/kg/day for acute-duration exposure derived in the 1994 Toxicological Profile for Methoxychlor. This MRL was based on precocious opening (early puberty) observed in rats exposed to 25 mg/kg/day (Gray et al., 1989). This study did not test doses as low as the current intermediate-duration MRL study (Chapin et al., 1997), which demonstrated the same effect from 5 mg/kg/day administered from gestation day 14 to postnatal day 42. Another example is the MRL for 2,3,7,8-tetrachlorodibenzo-p-dioxin. In 1989, the LOAEL of 0.001 µg/kg/day was considered for derivation of the intermediate-duration oral MRL of 1 pg/kg/day. At this exposure level, dilated pelvises and changes in gestational index were observed in rats (Murray et al., 1979). A UF of 10 was used for extrapolation from animals to humans, a factor of 10 for human variability, and a factor of 10 for the use of a LOAEL. The intermediate-duration exposure MRL was adopted for chronic exposure. No UF was used to extrapolate across durations. In 1998, the chronic MRL of 1 pg/kg/day was based on a LOAEL of 0.12 ng/kg/day in monkeys administered in a diet for a total exposure of  $16.2 \pm 0.4$  months (Schantz et al., 1992). An uncertainty factor of 3 was used for extrapolation from animals to humans, a factor of 10 for human variability, and a factor of 3 for the use of a LOAEL. In summary, although based on a lower LOAEL, the final value is the same because of the decreased uncertainty. The uncertainty was decreased because of the greater knowledge about dioxins based on 10 years of intensive research featured in a vast literature database. From that resulted a greater confidence in the new value (De Rosa et al., 1999; Pohl et al., 2002).

Health-based guidance values are derived by other agencies around the world. We have compared the MRLs with the reference concentrations (RfCs) and reference doses (RfDs) derived by U.S. EPA. The RfCs and RfDs values were found posted on the Integrated Risk Information System site at www.epa.gov/iris. In July 2004, a total of 69 RfCs and 358 RfDs was listed on the IRIS web site. Of all the RfCs listed, five were based on reproductive effects. Four of the chemicals were not evaluated by ATSDR. Only one chemical, 1,2,-dibromo-3-chloropropane was evaluated by both agencies. The RfC of 0.0002 mg/m<sup>3</sup> (ppm) is identical to the ATSDR's derived MRL for intermediate-duration inhalation exposure. Of all the RfDs listed, 18 were based on reproductive effects. Eleven chemicals were not evaluated by ATSDR. Of the remaining seven chemicals with RfDs based on reproductive effects, only two

corresponding chemicals have MRLs based on reproductive effects. Both agencies have the same value of 0.005 mg/kg/day for methoxychlor. The RfD for RDX is 0.003 mg/kg/day, the intermediate-duration oral MRL is 0.03 mg/kg/day. However, considering that the RfD value is for chronic exposure and this MRL is for intermediate-duration exposure, the value would be virtually the same after extrapolation across duration. MRLs for the remaining chemicals are based on different end points but also are derived for durations other than chronic (ATSDR, 1996). A valid comparison cannot be made.

In conclusion, because of interspecies variability and multifactorial control mechanisms, it is often difficult to predict reproductive toxicity in humans based on animal studies. For example, fertility studies, especially in rodents, are relatively insensitive indicators of chemical toxicity. Normal male rodents produce numbers of sperm that greatly exceed the minimum requirements for fertility studies, while in humans, the sperm counts in many individuals approach the threshold for infertility (Kimmel et al., 1992). In contrast, fertility in rodents remains unchanged, even after a 90% reduction in sperm count (Meistrich, 1982; Robaire et al., 1984). Interspecies differences between fertility of female rodents and humans in regard to sensitivity to chemicals reflected as implantation losses were discussed above. Although this relative insensitivity of laboratory animals may have contributed to overall databases for individual chemicals, other end points proved to be more sensitive indicators of toxicity. This, in turn, accounts for fewer ATSDR's MRLs and EPA's RfCs and RfDs based on reproductive effects. Nevertheless, careful evaluation of the whole database for each chemical, enabled ATSDR to derive several MRLs on the basis of reproductive and endocrine effects. The MRLs were based on solid scientific information and current methodology for risk assessment of noncancer end points. They are subject to change if new information becomes available (ATSDR, 1996, 2003a,b; EPA, 1998).

## References

- Allen-Rowlands, C.F., Castracane, V.D., Hamilton, M.G., et al., 1981. Effect of polybrominated biphenyls (PBB) on the pituitary-thyroid axis of the rat. Proc. Soc. Exp. Biol. Med. 166, 506-514.
- Army, 1983. Determination of the chronic mammalian toxicological effects of RDX: twenty four months chronic toxicity/carcinogenicity study of hexahydro-1,3,5-trinitro1,3,5-triazine (RDX) in the Fisher 344 rat. Phase V, vol. 1, Contract no DAMD 17-C-9161. U.S. Army Medical Research and Development Command, Fort Detrick. Document no. AD A138550). (authored by Spanggord et al.), Frederick, MD.
- ATSDR (Agency for Toxic Substances and Disease Registry), 1990. Toxicological profile for acrylonitrile. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA.

- ATSDR (Agency for Toxic Substances and Disease Registry), 1992a.

  Toxicological profile for 1,2,-dibromo-3-chloropropane. U.S.

  Department of Health and Human Services, Public Health
  Service, Agency for Toxic Substances and Disease Registry,
  Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 1992b.

  Public health assessment guidance manual. U.S. Department of
  Health and Human Services, Public Health Service, Agency for
  Toxic Substances and Disease Registry, Atlanta, GA. NTIS PB92147164.
- ATSDR (Agency for Toxic Substances and Disease Registry), 1995a.

  Toxicological profile for RDX. U.S. Department of Health and
  Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 1995b.

  Toxicological profile for 1,3-dinitrobenzene. U.S. Department of
  Health and Human Services, Public Health Service, Agency for
  Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 1995c.
  Toxicological profile for diethyl phthalate. U.S. Department of
  Health and Human Services, Public Health Service, Agency for
  Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR, 1996. Minimal risk levels for priority substances and guidance for derivation. Federal Register 61 (101), 25873-25882.
- ATSDR (Agency for Toxic Substances and Disease Registry), 1997. Toxicological profile for cyanide. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 1998a.

  Toxicological profile for 2,4-dinitrotoluene. U.S. Department of
  Health and Human Services, Public Health Service, Agency for
  Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 1998b.
   Toxicological profile for chlorinated dibenzo-p-dioxins (CDDs).
   U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta. GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 1999.
  Toxicological profile for 2,4,6-trichlorophenol. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 2001a.
  Toxicological profile for iodine. U.S. Department of Health and
  Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 2001b. Toxicological profile for pentachlorophenol. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 2002a.

  Toxicological profile for hexachlorbenzene. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 2002b.

  Toxicological profile for di(2-ethyl-hexyl)phthalate. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 2002c. Toxicological profile for polybrominated biphenyls (PBBs) and polybrominated diphenyl ethers (PBDEs). U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA.
- ATSDR (Agency for Toxic Substances and Disease Registry), 2002d. Toxicological profile for methoxychlor. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA.